Phase 2 N=12 Cognitive Behavioral Therapy and the Nicotine Transdermal Patch for Cannabis Dependence and Nicotine Dependence
Cannabis Dependence · Nicotine Dependence
Primary: Cigarette Use — 12.6; 2.1 cigarettes/day
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=242 Safety and Efficacy Study of a New Treatment for Recurrent Symptoms of Oral Herpes Virus Infection
Oral Herpes Simplex
Primary: Proportion of Subjects Who Experience a New Cold Sore Outbreak That Proceeds to the Lesion Stage. Of Those Subjects That Take Study Medication (Experience a New Emerging…
Phase 2 N=250 Romiplostim Treatment of Thrombocytopenia in Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
MDS · Myelodysplastic Syndromes · Thrombocytopenia
Primary: Number of Clinically Significant Bleeding Events — 116; 178 events — p=0.13
Phase 2 N=615 A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Low-Dose ICS Therapy.
Asthma
Primary: Mean Change From Baseline in Trough (Evening Pre-dose and Pre- Rescue Bronchodilator) FEV1 at Week 8 — -0.065; 0.142; 0.173; 0.228 Liters — p=<0.001
Phase 2 N=607 Efficacy And Safety Of GW642444M Comparing Placebo In Adolescent And Adult Subjects With Persistent Asthma.
Asthma
Primary: Mean Change From Baseline in Clinic Visit Trough FEV1 at Day 28 (Last Observation Carried Forward [LOCF]) — 0.147; 0.212; 0.217; 0.278 Liters — p=0.208
Phase 2 N=41 Avastin/Temozolomide/Irinotecan for Unresectable/Multifocal Glioblastoma Multiforme
Glioblastoma Multiforme · Gliosarcoma
Primary: Response Rate — 22 percentage of participants
Phase 2 N=32 Vinflunine Plus Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2neu) Over-Expressing Metastatic Breast Cancer
Breast Neoplasms · Breast Cancer
Primary: Overall Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment — 9; 33 percentage of participants
Phase 2 N=52 Phase 2 Study in Vascular Inflammation on Patients After an Acute Coronary Syndrome Event
Acute Coronary Syndrome
Primary: Change From Baseline in Plaque Imaging After 24 Weeks — -0.01; -0.06 TBR — p=0.34
Phase 2 N=40 Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS)
Acute Myelogenous Leukemia · Myelodysplastic Syndrome
Primary: Number of Participants With a Complete Response — 10 Participants
Phase 2 N=26 A Study in Asthmatic Patients to Determine if There is Any Difference in Dosing With Fluticasone Furoate/Vilanterol Inhalation Powder in the Morning or Evening on Lung Function
Asthma
Primary: Weighted Mean Forced Expiratory Volume in One Second (FEV1) Over 0-24 Hours Post-dose on Day 14 — 2.811; 3.188; 3.233 Liters
Phase 2 N=26 Inhaled Fluticasone Furoate/Vilanterol Safety and Tolerability, PK and PD Study
Asthma
Primary: Number of Participants With Any Adverse Event (AE) or Any Serious Adverse Event (SAE) During the Treatment Period — 4; 1; 0; 0 Participants
Phase 2 N=27 Randomised Study Comparing the Effects of Inhaled FF/GW642444M Combination, FF and GW642444M on an Allergen Induced Asthmatic Response
Asthma
Primary: Late Asthmatic Response (LAR): Absolute Change From Saline in Minimum FEV1 Between 4-10 Hours (Hrs) Following the 1-hr Post-treatment Allergen Challenge on Day 21 of…
Phase 2 N=17 GM-CSF in Treating Patients With Relapsed Prostate Cancer
Prostate Cancer
Primary: Prostate Specific Antigen (PSA) Response — 2; 0 participants
Phase 2 N=164 Evaluation of the Safety and Effectiveness of the CorPath 200 System in Percutaneous Coronary Interventions (PCI)
Coronary Artery Disease · Coronary Disease · Myocardial Ischemia
Primary: Percentage of Participants With Clinical Procedural Success — 97.6 percentage of participants
Phase 2 N=22 Rituximab in the Treatment of Scleritis and Non-Infectious Orbital Inflammation
Scleritis · Orbital Disease
Primary: Reduction of Medications — 5; 4 participants